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The human body hosts a series of dynamic and diverse microbial 
communities consisting of bacteria, archaea, viruses and eukaryotes, 
collectively known as the human microbiome. The microbiome plays 
a critical role in health and disease and has been shown to influence 
various medical conditions, ranging from diabetes to multiple 
sclerosis, autism, cancer and inflammatory bowel disease.[1]
Globally there has been a rapid increase in research and scientific 
publications predominantly on the gastrointestinal (GIT) microbiome 
and its role in health, immunology and nutrition. Therapeutic 
applications are of great interest, and a successful example is 
faecal microbiota transplantation (FMT). This process involves 
the introduction of gut bacteria from healthy donors into patients, 
with the aim of repairing the abnormal microbial community 
in the recipient. The efficacy of FMT for treatment of recurrent 
Clostridioides difficile infection (CDI) is a crucial proof of the concept 
that therapeutic modification of the GIT microbiome can be an 
effective treatment modality for human disease.[2] Other indications 
for FMT are also currently being explored.[3]
The legal regulation of microbiome-based therapy is difficult to 
categorise, however, as it poses an uncomfortable fit in terms of the 
South African (SA) legal framework governing the use of human 
tissue, as well as the legal regulation of medicines and medical 
devices.[2] More specifically, human stool banking or creation of a 
repository is critical to an FMT service. The purpose of this article 
is to explore the use of FMT as a microbiome-based therapy in SA 
by exploring the nature of FMT, followed by the role of FMT in 
clinical practice and then indicating the legal vacuum in which FMT 
currently exists.
The need for legal clarity on the regulation of FMT is underscored 
by a recent safety alert issued by the US Food and Drug Administration 
(FDA) regarding the transmission of a multidrug-resistant organism 
that resulted in two immunocompromised patients developing 
bacteraemia following an FMT.[4] This incident led to the death of one 
patient, and subsequent investigation found that the donor had not 
been screened for extended-spectrum beta-lactamase organisms.[5-7]
Understanding the role of the 
microbiome
Microbial cells outnumber human cells by approximately three to 
one.[8] The combined microbial genome encodes 500 times more 
genes than the human genome. The human microbiota refers to all 
the micro-organisms residing in the human body. The microbiome 
includes all the microbiota, and their genetic products – proteins, 
metabolites and RNA.[9,10]
The human gut has the largest collection of microbes, producing 
signals that influence host metabolic, immune and physiological 
functions. The five most abundant bacterial phyla found in 
healthy individuals are Bacteroidetes, Firmicutes, Actinobacteria, 
Proteobacteria and Verrucomicrobia. Within each phylum there are 
hundreds of bacterial species, each found in different abundances 
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in healthy individuals.[11,12] Gut bacterial lineages are highly 
variable, making a healthy core microbiome difficult to describe 
at organism phylum level. Shared microbial genes in the gut of 
different individuals indicate a common functional core microbiome 
at the gene level,[13] implying that different microbes have similar 
metabolites or functions and the absence of a single bacterial species 
may not be impactful.[14]
A healthy microbiome consists of a diverse assembly of microbial 
species in specific anatomical niches carrying out their specific 
biomolecular function. High microbial alpha diversity is associated 
with host health and microbial stability to environmental pressures. 
Alpha diversity can be described as the number of different microbial 
taxa and their abundance in an ecosystem.[15] Dysbiosis is a term 
that refers to disruption of the normal gut microbiome (e.g. a 
decrease in microbial alpha diversity) and is associated with various 
diseases such as obesity,[16] inflammatory bowel disease, autoimmune 
disease, allergy and diabetes.[17] Broad-spectrum antibiotics can 
decrease microbial diversity with variable recovery dynamics. When 
healthy gut microbes are diminished, they are unable to compete 
against pathogens wanting to colonise the gut.[18] In addition, 
certain beneficial microbes that produce beneficial metabolites 
(e.g. short-chain fatty acids (SCFAs)) perform important metabolic 
functions (e.g. metabolism of bile salts), produce anti-inflammatory 
metabolites or enhance gut epithelial function, and may be lost due 
to antibiotics or disease.
There are several factors that influence the microbiome during 
early life. Significant ones include mode of delivery (normal vaginal 
delivery v. caesarean section), gestational age at delivery,[19] infant 
feeding patterns (breastfed v. formula fed) and weaning foods,[20] 
antibiotic use,[21] and maternal factors such as health and diet. [13] 
A  recently published study that included the largest dataset of 
children born by either caesarean section or vaginal delivery 
demonstrated persistent significant differences in the microbial 
community composition associated with mode of delivery.[22] The 
gut microbiome undergoes substantial changes or maturation during 
the first 3 years of life and contributes to the development and 
maturation of the child’s immune system. By the age of 3, the child’s 
microbiome resembles that of an adult.[23]
The ongoing composition of the microbiome is influenced by host 
genetics to a limited extent and more significantly by environmental 
factors. Age, sex, geographical location, chronic disease, diet, 
medication (specifically antibiotics) and other environmental 
exposures (chemical or microbial) all play a role. Diet greatly shapes 
gut microbiota and may explain the geographical variation observed 
between populations on different continents.[18]
Gut-derived signalling molecules influence peripheral organs 
and metabolism. Signalling molecules can be part of the bacterial 
structure, such as lipopolysaccharide, which interacts with host 
receptors to produce an immunological response. Other important 
signalling molecules are byproducts of bacterial metabolism and are 
influenced by diet, such as SCFAs. Gut microbiota can be considered 
as a separate organ that influences the immune system, brain, lung, 
liver, skin, adipose tissue and metabolism. The microbiome-gut-brain 
axis refers to the myriad effects that the gut microbiota has on the 
brain and its functions.[10]
FMT is one modality that is used to manipulate the microbiome. 
Other techniques include probiotics, diet, phage therapy and 
antibiotics. Extensive data suggest that FMT can restore the healthy 
intestinal microbiome in a patient by enabling engraftment of donor 
microbes into recipients.[24]
C. difficile is an anaerobic, spore-forming, Gram-positive intestinal 
pathogen that is present in our environment and can asymptomatically 
colonise a healthy host. CDI occurs when bacterial toxins cause 
diarrhoea, and in certain patients this progresses to a life-threatening 
colitis. Dysbiosis of the gut microbiome caused by antibiotic use 
is the main risk factor for CDI. The first-line treatment for CDI 
is administration of antibiotics directed against CDI, but despite 
various dosing regimens for oral vancomycin, 20% of patients go on 
to develop recurrent CDI. Recent US and European guidelines now 
support the use of FMT to treat recurrent CDI.[24,25] Meta-analysis of 
randomised controlled trials and case series indicates a cure rate of 
80 - 90% with a single treatment, but some patients will require more 
than one FMT.[26] Current evidence suggests that FMT is a safe and 
well-tolerated procedure in patients with recurrent CDI.[26,27]
To date, a single USA-based stool bank, OpenBiome, has treated 
>50 000 patients with recurrent CDI and currently supports >30 
enrolling FMT clinical trials globally. This stool banking model 
(based on the blood banking model) is critical to an FMT service 
from both doctor/patient access and research perspectives. Prior 
to the expansion of stool banks, patients were required to identify 
their own donors who would need to be consented and screened 
by the treating doctor, a process that was prohibitively expensive 
and introduced ethical concerns around coercion and disclosure 
from patient-selected donors.[3,28] In addition, the collection and 
processing of the material was unpleasant and beyond the scope 
of most doctors. These factors were reported as major barriers to 
access to FMT for both patients and doctors.[29] The stool bank 
model removed many of these barriers and enabled almost universal 
access to FMT in the USA.[3] In the stool bank model, prospective 
donors undergo a detailed clinical assessment aimed at ruling out 
those who are an infectious risk or have a personal or immediate 
family history of microbiome-mediated diseases such as autoimmune 
disease, allergy, neuropsychiatric disease, malignancy, etc. Thereafter, 
prospective donors undergo extensive blood and stool tests for 
potential pathogens.[30]
Those who pass this process are onboarded as stool donors and 
undergo repeat clinical and laboratory screening at 2-monthly 
intervals, in addition to brief clinical assessment at each donation, 
to ensure that there has been no acute change in the donor’s health 
status. Stool is frozen in a cryopreservative buffer and stored at –80oC 
until needed. In addition, a safety aliquot is retained from each 
sample that is donated. This safety aliquot can be used for pathogen 
testing during investigation of an adverse event. Owing to the 
theoretical risk of transfer of inflammatory disease from donors to 
recipients, stool banks aim to retain data and samples from donors for 
extended periods.[25] The American Gastroenterological Association 
has established an FMT registry in the USA that aims to prospectively 
follow up patients, adult and paediatric, up to 10 years after FMT, 
with the aim of establishing long-term safety data.
Regulatory challenges to date
Regulatory challenges in the USA and Europe are one of the main 
reasons why FMT is not widely adopted among doctors. In 2013, 
the FDA announced that FMT would be regulated as a biological 
and as an investigational drug.[31] An initial regulation was that an 
investigational new drug (IND) application was required for access 
for all disease indications. Following the landmark paper by Van 
Nood et al.[32] in 2013, demonstrating significantly superior efficacy 
of FMT over placebo or standard of care in recurrent CDI, and 
subsequent pressure from providers and patients, the FDA chose to 
exercise enforcement discretion regarding the requirement for an 
IND requirement to treat recurrent CDI, thereby allowing clinicians 
and patients to access FMT. The use of FMT to treat any other 
disease indication would, however, require an IND application. 
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Another significant barrier for doctors and patients was access to 
material for treatment. The study by Lee et al.,[33] which demonstrated 
similar efficacy of frozen v. fresh FMT, catalysed the development 
of the universal donor stool bank. In this model, donors could be 
thoroughly screened and material banked for convenient future use 
by doctors.[33]
In 2016, a draft guidance statement from the FDA raised a safety 
concern related to the use of banked stool samples.[31] It proposed 
that stool banks would be required to submit an IND application 
to obtain and distribute stool. The draft guidance would not affect 
clinicians who were collecting and screening patient-selected donor 
stools. A safety concern of the FDA was that centralised stool banking 
may lead to a relatively small number of donors providing material 
to multiple patients. Potential transmission of infectious agents and 
other unidentifiable risks related to the microbiome of the few donors 
would reach many recipients.[31]
Criticism of the proposed regulation change was raised among 
both clinicians and consumers, and the draft guidance was never 
implemented. Owing to the ease of access to safe material using 
a stool bank, most medical facilities in the USA choose to use 
stool bank material for FMT. Stools for banking undergo extensive 
investigation for transmissible pathogens, as opposed to direct 
donation, where quality control is not possible.[31] Stool banks offer 
a centralised point of reference for safety monitoring and regulatory 
oversight and reduce costs through economies of scale.
A recent framework has been proposed in the USA that allows 
the degree of manipulation of the donor faecal material to determine 
the regulatory category.[34,35] Faecal material from a donor that 
is not manipulated or minimally manipulated (e.g. addition of 
a cryopreservative buffer or saline homogenisation) would be 
considered practice of medicine and not subject to federal regulation. 
When stools are manipulated and consist of defined bacterial 
populations, faecal material would fall under a traditional drug 
category. Stool banks would fall under a regulatory category like that 
of a tissue or blood bank.
Based on the successful US model of a stool bank of having treated 
>50 000 patients with only two adverse events, the ideal scenario 
would be to replicate this model in the SA and African context, while 
at the same time adapting it to the local context and disease burden. 
In order to ensure that FMT is performed safely, and is accessible to 
doctors, patients and researchers, SA must carefully consider how 
best to regulate stool banks and FMT.
Nature of FMT for the purpose of 
legal regulation
It seems as if stool donations would fall within the scope of the 
definition of ‘biological material’ as defined in the 2012 Regulations 
on the Use of Human Biological Material,[36] promulgated in terms of 
the National Health Act 61 of 2003 (NHA), which refers to biological 
material as ‘material from a human being’. The use of stool samples 
in FMT is not covered directly by these regulations or any other 
provisions in the NHA itself. The nature of FMT is equally unclear, as 
it is difficult to determine whether the procedure should be regarded 
in law as a medicine or a medical treatment.
The nature of FMT is unique and different from conventional 
medicines or therapies. It may include characteristics and components 
of a ‘health service’ in terms of the NHA, which include medical 
treatment, or a ‘medicine’ as described in the Medicines and Related 
Substances Control Act 101 of 1965. Each of these has different legal 
and ethical considerations, depending on the nature of the procedure.
If administered orally by way of swallowing capsules, FMT will 
arguably be regarded as a medicine. The administration of FMT via 
a nasoduodenal tube or colonoscopy resembles medical treatment. 
The confusion regarding the exact nature of FMT is also evident 
from the FDA’s position on the issue, which has shifted a few times in 
recent years. As mentioned above, the FDA currently classifies FMT 
as a drug (e.g. a live biotherapeutic product), subject to enforcement 
discretion of not requiring an IND for doctors performing the 
procedure for patients with recurrent CDI unresponsive to standard 
therapies.[31]
Regulatory systems may decide to regulate FMT as both a product 
and a procedure that combines approaches for the treatment of drugs, 
blood and human tissue for transplantation, or view it as part of the 
practice of medicine (e.g. clinical treatment). The regulatory pathway 
would depend on the exact composition of the FMT and the relevant 
formulations or levels of manipulation of the stool, which may range 
from basic frozen stool to capsules containing frozen or lyophilised 
stool, or defined consortia of bacteria.[35] Stool-based products 
containing specific bacterial strains aimed at treating specific diseases 
involve a higher level of manipulation and therefore a more target-
specific approach.
In the most elementary FMT procedure, faeces are liquefied, and 
saline or glycerol (e.g. a cryopreservative) added, which points to 
minimal manipulation. The FDA’s definition of ‘minimal manipulation’ 
of cells or non-structural tissue in the case of the transplantation of 
human cells and tissues refers to ‘processing that does not alter the 
relevant biologic characteristics of cells or tissue’.[37] This prompts the 
question regarding what the original relevant characteristics of stool 
are, and how one knows that these have changed. Ossorio and Zhou[38] 
rightly remark that if the scientific community has not adequately 
characterised the health-related functions of microbes in complex 
communities, considering that ‘people’s microbial communities 
are highly dynamic, then clinicians and regulators lack metrics for 
determining when a microbial community’s relevant properties have 
been altered by manipulation’.
According to Hoffmann et al.,[35] the degree of manipulation of stool 
may vary as follows from the least to the most manipulated: (i) fresh 
stool transferred from an individual donor; (ii) frozen filtered stool 
from a stool bank; (iii) concentrated stool microbiota in capsule form; 
(iv) biologically sourced, purified microbial groups of specific bacterial 
strains; and (v) cultured bacterial mixture delivered in oral pill form.
In the USA, stool that is extensively manipulated, isolated or 
combined with other components, or used for novel functions, 
would therefore be regulated under section 351 of the Public Health 
Services Act (2012) and the Federal Food, Drug, and Cosmetic Act 
as biological drugs or devices requiring premarket approval under 
Title 21 of the Code of Federal Regulations (1271.20), as stated above. 
Determining whether manipulated stool is a product or a procedure 
may also require characterisation of the stool (e.g. to document the 
structure and properties of the material). The regulatory process for 
live biotherapeutic products traditionally requires characterisation of 
all the microbes in the faecal material, which would require whole-
community genome sequencing of all the microbes contained in 
the stool.[28] This would not only be scientifically challenging but 
impossible, because human stool differs biologically and chemically 
considerably from one person to the next, rendering the regulatory 
requirement of consistency in product composition unfeasible.[28]
There is no doubt that FMT using single-donor stool (e.g. from 
a friend or relative) creates fewer risks, and it is for this reason that 
the recent draft FDA guidance document makes provisions for an 
‘enforcement discretion’ when ‘the stool donor and stool are qualified 
by screening and testing performed under the direction of the 
licensed healthcare provider for the purpose of providing the FMT 
product for treatment of the patient’.[37] The same cannot be said for 
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public health risks associated with universal donors or pooled stool. 
In the case of pooled stool from multiple donors, it is possible that 
unknown interactions between different microbial communities and 
increased risk of infection may arise.[28] The complexity with pooled 
stool is that it is difficult to trace the source of infection back to the 
actual donor. Ossorio and Zhou,[38] however, in response to Hoffmann 
et al.,[35] maintain that ‘if stool composition is dynamic and difficult 
to characterize, then a minimally-manipulated stool product for 
allogeneic transplant is possibly the most dangerous type of microbial 
product for a recipient. Compared to highly-manipulated but better 
characterized stool-derived products, stool from an asymptomatic 
donor is more likely to contain novel or uncharacterized viruses, 
bacteria, or protozoa that could be pathogenic, particularly for an 
already sick recipient.’ However, the role of minimally manipulated 
stool (transplantation of the entire microbiome community from a 
healthy donor) should not be dismissed, as there may be currently 
uncharacterised features of stool (e.g. viral, fungal components or 
metabolites) that could convey beneficial effects in some diseases. In 
addition, the use of whole-stool FMT will provide scientific data to 
inform the future selection of specific beneficial microbes necessary 
to develop defined consortia.
It is clear from this discussion that the uncertainties regarding the 
nature of stool and stool-derived products will continue to hamper 
their effective classification.
Conclusions
FMT has been shown to be a novel, safe and effective treatment for 
recurrent CDI. Stool banks are instrumental in enabling access to 
FMT for patients and clinicians and help to catalyse research in the 
microbiome. However, the regulatory landscape in SA remains unclear. 
Microbial therapies such as FMT are necessary, especially in a time of 
rising microbiome-associated inflammatory diseases and increasing 
resistance to traditional antibiotics. FMT is now considered as part 
of standard of care for recurrent CDI overseas, but is currently only 
being used for research purposes or in a minority of clinical cases of 
CDI in SA. The advantages of the procedure are not disputed, but 
what is needed is clarity on the regulatory framework in which FMT 
is performed. This article recommends that the relevant regulatory 
pathway for FMT would depend on the exact composition of the FMT 
and the relevant formulations or levels of manipulation of the stool. In 
part 2 of this series of articles, the legal categorisation of human stool 
as human tissue will be considered, as well as the application thereof 
in clinical practice. This will involve an analysis of the relevant legal 
framework to determine how FMT will be regulated in SA in future. 
The fact that FMT is still in a research phase in SA also has peculiar 
legal consequences that need to be explored. If the stool donations are 
processed and transformed into products, such as capsules, the legal 
framework may change completely. These issues will be interrogated 
further in subsequent parts of this series of articles.
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